EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Evotec SE is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, financial performance shows declining revenue and negative margins, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. Holding off on investment until clearer growth trends or positive signals emerge would be prudent.
The technical indicators are bearish. The MACD is below zero and negatively contracting, RSI is neutral at 40.56, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest limited upward momentum, with the price near support at 3.353.
Berenberg initiated coverage with a Buy rating and a EUR 10 price target, citing a leading position in drug discovery and favorable market trends.
The company's financials show declining revenue (-5.70% YoY) and negative gross margins (-100.40% YoY). No recent news or significant insider or hedge fund activity. Technical indicators are bearish, and there are no trading signals from AI Stock Picker or SwingMax.
In Q3 2025, revenue dropped by 5.70% YoY to 191,553,770.13. Net income improved but remains negative at -50,360,780.86 (+15.65% YoY). EPS increased to -0.28 (+12.00% YoY), and gross margin dropped significantly to -0.04 (-100.40% YoY).
Berenberg initiated coverage with a Buy rating and a EUR 10 price target, citing strengths in drug discovery and favorable market trends. However, no other analysts have provided recent updates specific to Evotec SE.
